PIK3CA
Showing 1 - 25 of >10,000
PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)
Completed
- PIK3CA Mutation-Related Tumors
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 9, 2023
HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)
Active, not recruiting
- HER2-positive Breast Cancer
- PIK3CA analysis
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
Patterns Among PIK3CA Mutation in Advanced Breast Cancer
Completed
- Breast Cancer
-
East Hanover, New JerseyNovartis
Aug 1, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Not yet recruiting
- PIK3CA-related Overgrowth Spectrum
- +8 more
- national registry
-
Paris, FranceTranslational medicine and Targeted therapies unit, Hôpital Neck
Sep 28, 2022
Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)
Recruiting
- Endometrial Cancer
- Ovarian Cancer
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2022
Health-related Quality of Life, Symptom Severity, and Pain Among
Recruiting
- PIK3CA-related Overgrowth Spectrum
- Alpelisib
-
East Hanover, New JerseyNovartis Investigative Site
Jun 14, 2022
HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)
Recruiting
- HER2-positive Metastatic Breast Cancer
- Alpelisib
- +2 more
-
Aurora, Colorado
- +2 more
Dec 29, 2022
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)
Recruiting
- Advanced Breast Cancer
-
Thalassery, Kerala, IndiaNovartis Investigative Site
Nov 21, 2022
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in
Recruiting
- Hormone Receptor Positive Breast Carcinoma
- +2 more
- Alpelisib
- +2 more
-
Chicago, Illinois
- +2 more
Jul 1, 2022
HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)
Not yet recruiting
- HER2-positive Breast Cancer
- Inavolisib
- +2 more
- (no location specified)
Mar 23, 2022
Tolerability Outcomes of Alpelisib in Real-world
Recruiting
- Breast Cancer
- alpelisib plus fulvestrant
-
Mumbai, Maharashtra, India
- +3 more
Jun 8, 2022
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation Trial in United States (Serabelisib, Insulin Suppressing
Recruiting
- Advanced Solid Tumor
- +2 more
- Serabelisib
- Insulin Suppressing Diet
-
Birmingham, Alabama
- +9 more
May 25, 2022
Study of Proteus Syndrome and Related Congenital Disorders
Recruiting
- Proteus Syndrome
- PIK3CA Related Overgrowth Spectrum
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 27, 2023
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome Trial in Worldwide (Miransertib)
Terminated
- PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
-
Atlanta, Georgia
- +10 more
May 10, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Biopsy
- +3 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 5, 2022